Drug Trial Radar · NCT01470118
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Feb 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Oct 2011
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- AllerganAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
Conditions
- Conjunctivitis, Allergic
Interventions
alcaftadine 0.25% ophthalmic solutionDrug
One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
olopatadine 0.2% ophthalmic solutionDrug
One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%Drug
One drop of placebo instilled in each eye at Day 0 and Day 14.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 0 at Hour 16Time frame: Day 0 Hour 16
- Ocular Itching Evaluated by the Subject at 3, 5, and 7 Minutes Post Challenge on Day 14 at Hour 24Time frame: Day 14 Hour 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.